Results 1 to 10 of about 49,425 (241)
Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters
Pharmaceutics, 2021 Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies +5 more
doaj +1 more source
Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19 [PDF]
, 2022 Remdesivir is the first US Food and Drug Administration (FDA)-approved drug for the treatment of coronavirus disease 2019 (COVID-19). We conducted a retrospective pharmacogenetic study to examine remdesivir-associated liver enzyme elevation among Million
Chanfreau, Catherine +18 more
core +1 more source
Diagnosis and Management of COVID-19 Disease [PDF]
, 2020 SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham +5 more
core +1 more source
Antimicrobial Agents and Chemotherapy, 2021 In December 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China and found to cause acute respiratory symptoms and pneumonia.1….
Bonnie C Prokesch, Brian J. Hopkins
openaire +4 more sources
Remdesivir for patients with COVID-19 [PDF]
Canadian Medical Association Journal, 2021 Remdesivir is an intravenous inhibitor of the viral RNA-dependent RNA polymerase with in vitro and in vivo activity against Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2.[1][1]–[3][2] In Canada, it is authorized ...
Andrew Morris, Peter E. Wu
openaire +3 more sources
Clinical and Translational Science, 2022 On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung +30 more
doaj +1 more source
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Clinical Outcomes of Remdesivir in COVID-19 Patients with Acute Kidney Injury or Chronic Kidney Disease: A Randomized Clinical Trial [PDF]
, 2023 Background: remdesivir is an RNA polymerase inhibitor approved to treat moderate to severe Coronavirus Disease 2019 (COVID-19); however, it has not yet been authenticated to apply to patients with acute kidney injury (AKI) or chronic kidney disease (CKD).
Alirezaei, Toktam +3 more
core +2 more sources
Role of Remdesivir therapy in COVID-19 patients: a systematic review and meta-analysis [PDF]
, 2022 The rapid global spread of corona virus disease has created an adversity for the scientific community in managing the disease with appropriate therapeutic measures.
Muthiah, Aravind +2 more
core +2 more sources
Remdesivir: First Approval [PDF]
Drugs, 2020 The antiviral agent remdesivir (Veklury®; Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID-19),
openaire +3 more sources